索拉非尼联合多柔比星对比索拉非尼单药治疗晚期肝细胞癌:CALGB 80802 III期随机临床试验
这项非盲III期随机试验纳入356例晚期肝细胞癌患者,比较索拉非尼联合多柔比星与索拉非尼单药的疗效。因无效边界在计划中期分析时被跨越,研究提前终止。联合组与单药组中位OS分别为9.3个月和9.4个月(HR 1.05),中位PFS分别为4.0个月和3.7个月(HR 0.93),联合治疗未改善OS或PFS。
要点
- 索拉非尼联合多柔比星未改善晚期肝细胞癌患者的总生存期。
- 联合组与单药组中位OS分别为9.3个月和9.4个月,HR 1.05。
- 联合组3/4级中性粒细胞减少和血小板减少发生率明显高于单药组。
核心结论
- 在晚期肝细胞癌患者中,索拉非尼联合多柔比星对比索拉非尼单药未改善总生存期或无进展生存期。
研究设计与样本
- 非盲随机III期临床试验,由Alliance牵头联合ECOG-ACRIN、加拿大癌症试验组和SWOG开展,2010年2月启动,2015年5月完成。
- 计划纳入480例患者,实际纳入356例(联合组180例,单药组176例),因计划中期分析跨越无效边界而提前终止。
- 入组标准为组织学证实的晚期肝细胞癌、未接受过系统治疗、Child-Pugh A级、ECOG体能状态0-2(后修订为0-1)且血液学、肝、肾和心功能充分。
主要发现
- 联合组中位OS为9.3个月(95% CI 7.3-10.8),单药组为9.4个月(95% CI 7.3-12.9),HR 1.05(95% CI 0.83-1.31)。
- 联合组中位PFS为4.0个月(95% CI 3.4-4.9),单药组为3.7个月(95% CI 2.9-4.5),HR 0.93(95% CI 0.75-1.16)。
- 联合组3/4级中性粒细胞减少61例(36.8%)、血小板减少29例(17.5%),单药组分别为1例(0.6%)和4例(2.4%)。
关键数值与推荐
- 联合组给药方案为多柔比星60 mg/m2每21天一次加索拉非尼400 mg口服每日两次;单药组为索拉非尼单药;胆红素1.3-3.0 mg/dL者减半剂量。
- 主要终点为OS,计划在480例患者中观察到364个事件,以90%把握度检测中位OS增加37%。
- 次要终点为PFS。
临床怎么用
- 不推荐在晚期肝细胞癌中常规将多柔比星加入索拉非尼治疗。
- 联合方案伴随更高的3/4级血液学毒性,选择方案时需权衡毒性。
局限性
- 研究因无效提前终止,实际样本量(356例)低于计划样本量(480例)。
- 研究为非盲设计。
- 入组标准中ECOG体能状态后来由0-2修订为0-1。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Previous communication has reported significant improvement in overall survival (OS) when using doxorubicin plus sorafenib in the treatment of advanced hepatocellular cancer (HCC). OBJECTIVE: To determine if doxorubicin added to sorafenib therapy improves OS, with stratification for locally advanced and metastatic disease. DESIGN, SETTING, AND PARTICIPANTS: This unblinded randomized phase 3 clinical trial was led by Alliance in collaboration with Eastern Cooperative Oncology Group-American College of Radiology Imaging Network, Canadian Cancer Trials Group, and Southwest Oncology Group. It was launched in February 2010 and completed in May 2015; data were also analyzed during this time frame. Patients with histologically proven advanced HCC, no prior systemic therapy, Child-Pugh grade A score, Eastern Cooperative Oncology Group performance status of 0 to 2 (later amended to 0-1), and adequate hematologic, hepatic, renal, and cardiac function were eligible. The OS primary end point had a final analysis planned with 364 events observed among 480 total patients with 90% power to detect a 37% increase in median OS. INTERVENTIONS OR EXPOSURES: Patients received either 60 mg/m2 of doxorubicin every 21 days plus 400 mg of sorafenib orally twice daily or the sorafenib alone, adjusted to half doses for patients with bilirubin levels of 1.3 to 3.0 mg/dL. MAIN OUTCOMES AND MEASURES: The primary end point was OS, and progression-free survival (PFS) was a secondary end point. RESULTS: Of 356 patients included in the study, the mean (SD) age was 62 (10.1) years, and 306 (86.0%) were men. Although it was planned to include 480 patients, the study was halted after accrual of 356 patients (180 patients treated with doxorubicin plus sorafenib and 176 with sorafenib alone) with a futility boundary crossed at a planned interim analysis. Median OS was 9.3 months (95% CI, 7.3-10.8 months) in the doxorubicin plus sorafenib arm and 9.4 months (95% CI, 7.3-12.9 months) in the sorafenib alone arm (hazard ratio, 1.05; 95% CI, 0.83-1.31). The median PFS was 4.0 months (95% CI, 3.4-4.9 months) in the doxorubicin plus sorafenib arm and 3.7 months (95% CI, 2.9-4.5 months) in the sorafenib alone arm (hazard ratio, 0.93; 95% CI, 0.75-1.16). Grade 3 or 4 neutropenia and thrombocytopenia adverse events occurred in 61 (36.8%) and 29 (17.5%) patients, respectively, being treated with doxorubicin plus sorafenib vs 1 (0.6%) and 4 (2.4%) patients treated with sorafenib. CONCLUSIONS AND RELEVANCE: This multigroup study of the addition of doxorubicin to sorafenib therapy did not show improvement of OS or PFS in patients with HCC. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01015833.
引用
- Abou-Alfa GK, Shi Q, Knox JJ, et al. Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical Trial. JAMA Oncol. 2019. PMID: 31486832. doi:10.1001/jamaoncol.2019.2792
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。